Kyowa-Amgen Antibody Deal Worth Up To $520 Million
This article was originally published in PharmAsia News
Executive Summary
Kyowa Hakko struck a deal worth as much as $520 million with Amgen to outlicense a monoclonal antibody Amgen will develop first for inflammatory disease indications, the firms said March 5